1. Home
  2. ALTI vs GLSI Comparison

ALTI vs GLSI Comparison

Compare ALTI & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AlTi Global Inc.

ALTI

AlTi Global Inc.

HOLD

Current Price

$3.79

Market Cap

412.6M

Sector

Finance

ML Signal

HOLD

Logo Greenwich LifeSciences Inc.

GLSI

Greenwich LifeSciences Inc.

HOLD

Current Price

$26.02

Market Cap

372.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALTI
GLSI
Founded
2020
2006
Country
United States
United States
Employees
490
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
412.6M
372.0M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
ALTI
GLSI
Price
$3.79
$26.02
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$50.00
AVG Volume (30 Days)
143.9K
131.8K
Earning Date
05-11-2026
05-19-2026
Dividend Yield
N/A
N/A
EPS Growth
41.11
N/A
EPS
N/A
N/A
Revenue
$254,956,000.00
N/A
Revenue This Year
$18.06
N/A
Revenue Next Year
$10.71
N/A
P/E Ratio
N/A
N/A
Revenue Growth
23.21
N/A
52 Week Low
$2.96
$7.78
52 Week High
$5.45
$34.10

Technical Indicators

Market Signals
Indicator
ALTI
GLSI
Relative Strength Index (RSI) 48.36 53.00
Support Level $3.76 $21.20
Resistance Level $3.92 $30.02
Average True Range (ATR) 0.22 1.87
MACD 0.06 0.38
Stochastic Oscillator 70.67 71.65

Price Performance

Historical Comparison
ALTI
GLSI

About ALTI AlTi Global Inc.

AlTi Global Inc is a wealth and investment partner to families, foundations, and institutions, helping clients activate capital, bring structure to complexity, and plan across borders and generations. The company combines the breadth of an international firm with the service offering of a family office to deliver solutions for wealth and capital. It provides services including discretionary and non-discretionary investment advisory, estate and wealth planning, trust and fiduciary, governance, philanthropy, and family office services, along with access to alternative investment opportunities. The company generates revenue from management, advisory, trustee, or administration fees, performance or incentive fees, distributions from investments, and other income or fees.

About GLSI Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.

Share on Social Networks: